AstraZeneca COVID-19 vaccine achieves 70% efficacy AstraZeneca released interim analysis from clinical trials of AZD1222, its COVID-19 vaccine candidate in the U.K. and Brazil, with data demonstrating it met the primary endpoint of preventing COVID-19.
FDA issues EUA for Regeneron's COVID-19 mAb cocktail The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) on November 21 for the casirivimab and imdevimab monoclonal antibody (mAb) cocktail. The mAb cocktail is for the treatment of mild to moderate symptoms in patients with COVID-19 who are at a high risk for progressing to severe COVID-19.
FDA to review Pfizer, BioNTech's vaccine EUA on December 10 The Vaccines and Related Biological Products Advisory Committee of the U.S. Food and Drug Administration (FDA) has set a date of December 10 to discuss the request for emergency use authorization (EUA) of Pfizer and BioNTech's COVID-19 vaccine candidate.
Dr. Anthony Fauci breaks down the importance of COVID-19 vaccines Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, discussed the perils and opportunities of public trust during the COVID-19 pandemic, especially pertaining to the development of vaccines. The conversation took place on November 19 and was part of the Hastings Center's series Securing Health in a Troubled Time.